Common Cold News and Research RSS Feed - Common Cold News and Research

Scientists unveil structure of Zika NS1 protein

Scientists unveil structure of Zika NS1 protein

Researchers have revealed the molecular structure of a protein produced by the Zika virus that is thought to be involved in the virus's reproduction and its interaction with a host's immune system. [More]
Scientists uncover structure of cold virus linked to severe asthma, respiratory infections in children

Scientists uncover structure of cold virus linked to severe asthma, respiratory infections in children

The atomic structure of an elusive cold virus linked to severe asthma and respiratory infections in children has been solved by a team of researchers at the University of Wisconsin-Madison and Purdue University. [More]
Zinc acetate lozenges may be effective in treating common cold

Zinc acetate lozenges may be effective in treating common cold

Zinc acetate lozenges may reduce the duration of the common cold by nearly 3 days, according to a recent analysis. [More]
Bringing healthcare home: an interview with Dr Andrew Lin

Bringing healthcare home: an interview with Dr Andrew Lin

The goal of CliniCloud is to bring healthcare home. For us, what that means is a patient-centered and patient-modeled healthcare system, where we focus on the fact that consumers want access to healthcare and to a doctor. We're building an ecosystem around the tools and the software to really enable that to happen as conveniently and as affordably as possible. [More]
Common misconception about penicillin allergies

Common misconception about penicillin allergies

It's time for your primary care check-up, and the doctor asks you to list any known drug allergies. "Penicillin," you say immediately, although you can't remember actually taking the drug or having a reaction to it—it was your parents who said so. According to a Texas A&M Health Science Center allergist, many people who believe they're allergic to this antibiotic may not actually be allergic at all. [More]
Experimental therapy has over 90% remission rate for advanced leukemia patients

Experimental therapy has over 90% remission rate for advanced leukemia patients

Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (disease-fighting immune cells) were genetically engineered to fight their cancers. [More]
Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. [More]
Zika threat to Olympics attendees? An interview with Prof. Eskild Petersen

Zika threat to Olympics attendees? An interview with Prof. Eskild Petersen

The risk in terms of the Olympics, especially for travelling populations remains low – with the notable exception of pregnant women. [More]
Higher rates of breastfeeding, vaccination use cut ear infection in babies

Higher rates of breastfeeding, vaccination use cut ear infection in babies

In what would be considered good news for many parents a new study from The University of Texas Medical Branch at Galveston finds the rates of ear infections during a baby's first year have declined; the investigators suggested that higher rates of breastfeeding, use of vaccinations and lower rates of smoking may be the major contributors. The study was recently published in Pediatrics. [More]
Scientists start clinical trial to test new prostate cancer vaccine

Scientists start clinical trial to test new prostate cancer vaccine

Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield. [More]
Behavioral interventions motivate doctors to reduce unnecessary antibiotic prescriptions

Behavioral interventions motivate doctors to reduce unnecessary antibiotic prescriptions

Behavioral interventions that appealed to doctors' competitive spirits and desire to strengthen their reputations motivated them to significantly reduce unnecessary antibiotic prescriptions, a new study shows. [More]
Cold viruses at school largely to blame for asthma hospitalizations

Cold viruses at school largely to blame for asthma hospitalizations

The most dangerous times of year for children with asthma are soon after their schools reopen after a break, and a new study finds that cold viruses are largely to blame. [More]
Duke researchers closer to developing rapid blood test for bacterial and viral infections

Duke researchers closer to developing rapid blood test for bacterial and viral infections

Researchers at Duke Health are fine-tuning a test that can determine whether a respiratory illness is caused by infection from a virus or bacteria so that antibiotics can be more precisely prescribed. [More]
Study explores new approaches to prevent fall asthma exacerbations in pediatric patients

Study explores new approaches to prevent fall asthma exacerbations in pediatric patients

Experts from Children's Hospital Colorado (Children's Colorado) co-led a team of researchers in studying new approaches to reducing fall asthma exacerbations in pediatric patients. [More]
New vaccine shows promise against Middle East respiratory syndrome in dromedary camels

New vaccine shows promise against Middle East respiratory syndrome in dromedary camels

An international research project with the involvement of Universitat Autònoma de Barcelona and the Animal Health Research Centre (IRTA-CReSA), has designed a vaccine shown to be effective in protecting dromedaries against the coronavirus (CoV) that causes Middle East respiratory syndrome (MERS). [More]
Viralytics announces completion of $28 million placement

Viralytics announces completion of $28 million placement

Viralytics Limited announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736. [More]
Combination treatment provides effective one-two punch against prostate cancer

Combination treatment provides effective one-two punch against prostate cancer

Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease. [More]
SLU infectious diseases experts answer flu season questions

SLU infectious diseases experts answer flu season questions

A cure for the common cold isn't in the crystal ball of an infectious diseases researcher and physician at Saint Louis University's Center for Vaccine Development. [More]
Simple self-rating of health accurately predicts susceptibility to common cold

Simple self-rating of health accurately predicts susceptibility to common cold

New research from Carnegie Mellon University psychologists shows that a simple self-rating of health accurately predicts susceptibility to the common cold in healthy adults aged 18-55 years. Published in Psychosomatic Medicine, the study - led by CMU's Sheldon Cohen - indicates that low self-rated-health is associated with poorer immune system competence. [More]
Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy. [More]
Advertisement
Advertisement